semaglutide cardiovascular outcomes 2025 news today Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral Semaglutide and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis

23.67

★★★★☆4.8 (126)

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

25.92

★★★★★4.9 (98)

Population‐level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial - Nanna - 2025 - Diabetes, Obesity and Metabolism

23.49

★★★★★5.0 (157)

Long-Term SELECT Trial: Semaglutide Cuts Cardiovascular Events by 20% beyond Weight Loss

20.12

★★★★★4.7 (84)

🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants

24.00

★★★★★4.9 (203)

In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8

24.45

★★★★★5.0 (176)

Novo cuts GLP-1 prices 70%, but semaglutide revenue could grow in 2026

29.02

★★★★★4.8 (132)